Aug. 6 at 7:21 AM
$UPB 2/2
Nevertheless the 100-mg dose every 12 weeks clearly met the primary endpoint (the reduction in annual asthma exacerbations), namely 56% (p < 0.0003). In an indirect(!) comparison the 56% reduction with Verekitug is practically on par with that of tezepelumab or dupilumab, which are currently considered the most effective and most widely used biologics for asthma. But tezepelumab must be injected every 4 weeks. Verekitug could be administered every 12 weeks, which would mean only four injections per year. Currently UPB prepares for the Phase 2 completion discussions with the FDA, which are expected to take place in mid-2026. So they're still on track as far as I can see. As always: You do you, I might be wrong, so no advice - just some food for thought. Feel free to agree or disagree...
